Health Care [ 4/12 ] | Biotechnology [ 15/73 ]
NASDAQ | Common Stock
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers.
Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 17, 25 | -0.12 | - |
| Mar 11, 25 | -72.60 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | N/A Decreased by N/A% | -88.50 Increased by +99.98% | - - |
| Mar 31, 25 | N/A Decreased by N/A% | -88.50 Increased by +69.90% | - - |
| Dec 31, 24 | N/A Decreased by N/A% | -957.00 K Decreased by -133.99% | - - |
| Sep 30, 24 | N/A Decreased by N/A% | -478.50 Increased by +99.75% | - - |
| Jun 30, 24 | N/A Decreased by N/A% | -588.00 K Decreased by -214.44% | - - |
| Mar 31, 24 | N/A Decreased by N/A% | -294.00 Increased by +99.95% | - - |
| Dec 31, 23 | N/A Decreased by N/A% | -409.00 K Increased by +26.70% | - - |
| Jun 30, 23 | N/A Decreased by N/A% | -191.00 K Decreased by -24.84% | - - |